Healios K.K.
13
1
1
7
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 75/100
23.1%
3 terminated/withdrawn out of 13 trials
70.0%
-16.5% vs industry average
8%
1 trials in Phase 3/4
29%
2 of 7 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (13)
MultiStem® for Treatment of Trauma Induced Multiple Organ Failure/Systemic Inflammatory Response Syndrome
Role: lead
Efficacy and Safety Study of HLCM051(MultiStem®) for Pneumonic Acute Respiratory Distress Syndrome
Role: lead
Treatment Evaluation of Acute Stroke for Using in Regenerative Cell Elements
Role: lead
MultiStem® Administration for Stroke Treatment and Enhanced Recovery Study
Role: lead
MultiStem Administration for COVID-19 Induced ARDS (MACoVIA)
Role: lead
A Phase 2 Trial of AMI MultiStem® Therapy in Subjects With Non-ST Elevation Acute Myocardial Infarction
Role: lead
A Phase 1/2 Study to Assess MultiStem® Therapy in Acute Respiratory Distress Syndrome
Role: lead
Safety Study of Multipotent Progenitor Cells for Immunomodulation Therapy After Liver Transplantation
Role: collaborator
Study to Examine the Effects of MultiStem in Ischemic Stroke
Role: lead
A Study To Investigate The Safety And Possible Clinical Benefit Of Multistem(r) In Patients With Moderate To Severe Ulcerative Colitis
Role: collaborator
A Short-Term Study to Examine the Effects of ATHX-105 Phosphate on Weight Loss and Safety
Role: lead
Safety Study of AMI MultiStem® to Treat Heart Attacks
Role: lead
Safety Study of MultiStem® in Patients With Acute Leukemia, Chronic Myeloid Leukemia, or Myelodysplasia
Role: lead
All 13 trials loaded